基本信息:
- 专利标题： IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS
- 专利标题（中）：用于检测神经疾病的成像剂
- 申请号：PCT/US2010028360 申请日：2010-03-23
- 公开(公告)号：WO2010111303A2 公开(公告)日：2010-09-30
- 发明人： GANGADHARMATH UMESH B , KOLB HARTMUTH C , SCOTT PETER J H , WALSH JOSEPH C , ZHANG WEI , SZARDENINGS ANNA KATRIN , SINHA ANJANA , CHEN GANG , WANG ERIC , MOCHARLA VANI P , YU CHUL , LIU CHANGHUI , CASHION DANIEL KURT , KASI DHANALAKSHMI
- 申请人： SIEMENS MEDICAL SOLUTIONS , GANGADHARMATH UMESH B , KOLB HARTMUTH C , SCOTT PETER J H , WALSH JOSEPH C , ZHANG WEI , SZARDENINGS ANNA KATRIN , SINHA ANJANA , CHEN GANG , WANG ERIC , MOCHARLA VANI P , YU CHUL , LIU CHANGHUI , CASHION DANIEL KURT , KASI DHANALAKSHMI
- 专利权人： SIEMENS MEDICAL SOLUTIONS,GANGADHARMATH UMESH B,KOLB HARTMUTH C,SCOTT PETER J H,WALSH JOSEPH C,ZHANG WEI,SZARDENINGS ANNA KATRIN,SINHA ANJANA,CHEN GANG,WANG ERIC,MOCHARLA VANI P,YU CHUL,LIU CHANGHUI,CASHION DANIEL KURT,KASI DHANALAKSHMI
- 当前专利权人： SIEMENS MEDICAL SOLUTIONS,GANGADHARMATH UMESH B,KOLB HARTMUTH C,SCOTT PETER J H,WALSH JOSEPH C,ZHANG WEI,SZARDENINGS ANNA KATRIN,SINHA ANJANA,CHEN GANG,WANG ERIC,MOCHARLA VANI P,YU CHUL,LIU CHANGHUI,CASHION DANIEL KURT,KASI DHANALAKSHMI
- 优先权： US16242109 2009-03-23
- 主分类号： A61K51/04
- IPC分类号： A61K51/04 ; C07B59/00 ; C07D215/00 ; C07D235/04 ; C07D263/52 ; C07D277/62
摘要：
Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and ß-amyloid peptides are presented herein. The invention also relates to methods of imaging Aß and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disoders.
摘要（中）：
式（I）的成像剂和用于检测神经障碍的方法包括给予需要能够结合tau蛋白和β-淀粉样蛋白肽的式（I）化合物的化合物。 本发明还涉及成像Aβ和tau聚集体的方法，包括引入可检测量的包含放射性标记的式（I）化合物的药物制剂，并检测患者中与淀粉样蛋白沉积物和/或tau蛋白相关的标记化合物。 这些方法和组合使得AD和其他神经系统解剖器的临床前诊断和监测进展。
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K51/00 | 用于治疗或体内测试用的含有放射性物质的配制品 |
| --------A61K51/02 | .以载体为特征 |
| ----------A61K51/04 | ..有机化合物 |